Introduction
B cell non-Hodgkin's lymphomas (NHL) are a collection of highly heterogeneous lymphoproliferative disorders. Malignant cells are blocked at different stages of differentiation and this is believed to reflect the maturational stage of the normal lymphocyte counterpart from which the malignant cells arise.
Normal lymphocytes at different stages of maturation show different capacities to recirculate, to adhere to stromal cells, to grow within lymphoid tissues and to respond to T cell signals. Cellular adhesion molecules (CAMs) have been shown to be critical in these processes. [1] [2] [3] [4] [5] Since malignant cells may retain some of the attributes of their normal counterparts, it is possible that they use the same molecules to achieve the same functional outcome as normal cells. Indeed, CAMs have been shown to be involved in the proliferation and dissemination of tumour cells. [6] [7] [8] [9] [10] In the present work, we have studied five CAMs, CD54 (ICAM-1), CD58 (LFA-3), CD11a (␣L), CD29 (␤1) and CD49d (␣4), potentially involved in B lymphocyte co-operation with their microenvironment -especially, T lymphocytes [10] [11] [12] [13] [14] [15] and follicular dendritic cells. 2, 16 CD54 and CD58 belong to the Ig superfamily, and CD11a, CD29 and CD49d belong to the integrin family. 4 CD11a is always associated with CD18 to form the LFA-1 molecule, whereas CD49d can associate either with CD29 to form the VLA-4 molecule, or with ␤7 to form the ␣4␤7 integrin. 17 Within lymph nodes, CD54/LFA-1 and CD58/CD2 interactions are required for co-operation between B and T lymphocytes, respectively, whereas Correspondence: M-C Jacob, Laboratoire d'Immunocytologie, ETS Isère-Savoie, BP or salvage from apoptosis. 21 They are also essential for the cytotoxic function of NK and cytotoxic T lymphocytes. 22, 23 All these five CAMs were widely expressed in our series of lymphomas and the analysis of the percentage of positive cells did not allow discrimination between the NHL subtypes. However, as adhesion relies not only on the presence of CAMs, but also on their level of expression, 4, 14 we quantified their level of expression using a flow cytometric methodology. 24 Our results demonstrated that the expression of CAMs in B cell NHL varied depending on the subtype as defined by the REAL classification, 25 with each subtype showing a unique pattern of expression for the five CAMs tested. Overall, the level of CAM expression was highest in high grade NHL, ie the most activated malignant cells.
Materials and methods

Patients
Specimens from 114 patients (68 men and 46 women, mean age 63 years) with B-NHL were investigated for CAM expression. The diagnosis was confirmed by immunological, histological and cytogenetic analysis (data not shown). NHL were classified according to the REAL classification: 25 24 small lymphocytic lymphoma (SLL), 15 mantle cell lymphoma (MCL), 39 follicular lymphoma (FL), four lymphoplasmacytoid lymphoma (LPL), 31 diffuse large cell lymphoma (DLCL) including 22 centroblastic (DLCL-CB) and nine immunoblastic (DLCL-IB) lymphoma. SLL, MCL, FL and LPL are considered as low or intermediate grade NHL, whereas DLCL-CB and DLCL-IB are high grade NHL.
Biopsy specimens comprised 107 lymph nodes, eight spleens and two extranodal tumours. They were obtained either at the time of diagnosis (67 cases) or at relapse (46 cases). The sole selection criterion was the recovery of sufficient lymphocytes for analysis. Non-malignant B lymphocytes from lymph nodes with benign hyperplasia (10 cases) or Hodgkin's disease (two cases) were also included in this study.
Immunofluorescence labelling
All immunofluorescence analyses were performed on fresh cells. Whole lymph nodes were received immediately after excision. They were gently dissociated with a scalpel in RPMI 1640 medium (Gibco, Cergy Pontoise, France) and washed twice. Cells were first labelled using an indirect immunofluorescence procedure; briefly, 10 6 Lastly, cells were stained with 10 l phycoerythrin-CD19 (PE-CD19) to allow discrimination of B lymphocytes within the whole population. In NHL, all CD19-positive cells were malignant cells (more than 98% of CD19 + cells expressed only one kind of light chain ( or ) and one kind of heavy chain (except and ␦)). Negative controls were irrelevant mAb of the same isotype as CAM-mAbs (IgG1 or IgG2a). To identify activated B lymphocytes, cells were labelled with Ki67 mAb using an indirect immunofluorescence technique and saponin. 26 All the antibodies are listed in Table 1 . Fluorescence analysis was performed on a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA). 10 000 events were recorded for each sample.
Immunofluorescence quantification
CAM expression was measured by a quantification method previously described by Dawson et al. 24 We used this method with minor modifications as previously described in others reports. 27, 28 Briefly, CAM expression was quantified by measuring the mean value of green fluorescence (= CAM fluorescence) on B lymphocytes only; ie after gating on the red fluorescence events (= PE-CD19 + subset). The distribution of the fluorescence was always close to a gaussian distribution; so, the mean value on the fluorescence histogram was a good representative parameter. Standardisation was performed with fluorescent beads (Immunobrite; Coulter), which consisted of five calibrated populations with a known number of molecular equivalent of soluble fluorescein (MESF). Thus, using linear regression analysis, the mean value for CAM fluorescence could be transformed into a MESF value. The value obtained was corrected by subtracting the MESF value of the isotype-matched irrelevant mAb. This value was then divided by the fluorescein/protein ratio (= 4).
Statistical analysis
Statistical analysis was performed on a Macintosh computer, using Statview 4.02 software. Data correlation studies were 
Results
CAM expression on NHL subtypes according to the REAL classification
CAM expression was analysed on B lymphocytes using a quantitative flow cytometric assay, as described in Materials and methods and in previous reports. 27, 28 This produces a result expressed in standardised MESF units, thereby allowing comparison between different samples, even over long time intervals. A representative flow cytometric analysis is shown in Figure 1 . However, it should be noted that this technique does not allow determination of antigenic site numbers.
As shown in Figure 2 , CAMs were heterogeneously expressed by the different patients and between NHL subtypes according to the REAL criteria. CAM expression in non-malignant B cells is shown as indicative data. The Kruskall-Wallis test demonstrated significant differences between the NHL subtypes for each CAM (with a P value set at р0.001), apart from CD49d. Then, each NHL subtype was analysed for CAM expression against the other subtypes in a 2 by 2 comparison using the Mann-Whitney U test. Firstly, NHL entities which showed no statistical differences for the expression of a given CAM were classed together in the same group. For each CAM, three groups were identified based on the level of expression: weak, moderate or high (see Table 2 ). The group with the statistically lowest values defined the 'weak' level and the group with the highest values defined the 'high' level. Values between these two extremes represented the 'moderate' level of expression. All the cases could be classified according to these criteria, except for CD11a and CD58 expression on DLCL-CB.
This approach revealed that the heterogeneity of CAM expression was partly related to the degree of differentiation of the lymphoma cell. Thus, as shown in Table 2 , the lowest levels of expression for CD54, CD58, CD11a and CD29 were found among the low and intermediate grade NHL, while the highest levels of expression of these four CAMs were most consistently found in the high grade NHL. Nevertheless, each NHL subtype showed a unique profile with respect to CAM expression. For example, SLL was in the 'weak' group for CD54 and CD11a expression but in the 'high' group for CD58 and CD29. In contrast, FL showed low expression of CD58, CD11a and CD29 but intermediate levels of CD54. Thus, FL can be distinguished from SLL in terms of lower values of CD58 (P = 0.001), CD29 (P = 0.001) and higher values of CD54 (P = 0.0001); whereas FL differ from MCL by lower values of CD58 (P = 0.003) and CD29 (P = 0.0058), but not CD54 (P = 0.998). SLL could be distinguished from MCL by their stronger expression of CD58 (P = 0.0002) and weaker expression of CD54 (P = 0.0032). Within high grade NHL, no difference was demonstrated between DLCL-IB and DLCL-CB. One group of NHL was too small to allow statistical analyses: LPL (four cases), which belonged to the 'moderate' group for expression of CD54 and CD11a and to the 'high' group for CD58 and CD29. Non-tumoral B lymphocytes (nT) also showed a unique profile of CAM expression with low levels of CD58 and moderate levels of CD54 and CD11a, while CD29 expression was not statistically different from the other groups.
Therefore, high and low grade NHL can be separated on the basis of their level of expression of CAMs: as shown in Table 2 , DLCL-CB and DLCL-IB were in the group with high levels, whereas SLL, MCL and FL were found most often in the groups with weak or moderate levels of CAM expression.
CAM expression and malignant lymphocyte activation
Malignant NHL B lymphocytes demonstrated different degrees of activation as evaluated by positivity with the Ki67 mAb, which is a marker of the G1/S/G2 and M phase of the cell cycle. 29 The mean percentage of Ki67-positive cells was 50 ± 25% in high grade NHL and 10 ± 9% in low grade NHL. In this series of NHL, the percentage of Ki67-positive cells was only correlated (P = 0.0001, Spearman rank test) with the level of CD54 expression (Figure 3 ). This activation could reflect an intrinsic property of the malignant cells or could otherwise depend on contact with environmental cells and thereby involve adhesion molecules.
Discussion
In the present work, the level of five CAMs (CD54, CD58, CD11a, CD29 and CD49d) was analysed on malignant lymphocytes from a large number of B-NHL by flow cytometry in search of differential expression with regard to the various subtypes. 25 It was postulated that because these molecules are critical in normal lymphocyte functions, [1] [2] [3] [4] 19 they might also have an essential role in tumour characteristics and clinical behaviour. A great deal of evidence supports this hypothesis. 6, 7, 9, 10, 30 The simple determination of the percentage of positive cells did not discriminate between NHL. Since the peaks of fluorescence were always found to be unimodal, B lymphocytes from one biopsy are to be considered homogenous with regards to the analysed marker. So the best way to compare CAM expression is to consider the intensity of fluorescence. Furthermore, the level of CAM expression is important with respect to cell adhesion (for example, memory NHL have been classified using the results of the comparison by the Mann-Whitney U test. For each CAM, the group with the statistically lowest values determined the 'weak' level, the group with the highest values the 'high' level. Between them was the 'moderate level'. LPL could not be analysed statistically because of the low number of events in this group (n = 4). The median MESF value is shown for each CAM. In brackets are the 25th and 75th percentile. *Not statistically different from the other groups (median = 788, 25th percentile = 462, 75th percentile = 1180). **Not statistically different from the other groups (median = 477, 25th percentile = 247, 75th percentile = 1378). # Not statistically different from the other groups (median = 3986, 25th percentile = 2062, 75th percentile = 5833). mod, 'moderate' level of CAM expression; nT, non-tumoral B lymphocytes.
Figure 3
Correlation of CD54 expression to the % of Ki67 positivity.
T lymphocytes express more adhesion molecules than naive T lymphocytes and adhere more vigorously; 4,14 therefore, we quantified cell surface CAM expression as described in the Materials and methods section.
Quantification using flow cytometry has rarely been reported in the literature, [31] [32] [33] most studies being semi-quantitative analyses by immunohistochemistry. Here, using flow cytometric quantification, we have documented the heterogeneity of the level of CAMs in a large series of NHL and related this heterogeneity to the different entities described by the REAL classification. Thus, low grade NHL, that are developed essentially from naive B lymphocytes (MCL and SLL 34, 35 ) or recently activated B lymphocytes that have returned to a quiescent state (FL 36 ) expressed the lowest amount of CAMs. Conversely, high grade NHL, that arise from continuously activated cells, 25 express the highest amount of CAMs. It should be noted, however, that adequate adhesion is not only dependent on the level of CAM expression, since activity, especially for the integrin family, may also depend on an avid state of the molecule, due to conformational changes. 4 Unfortunately, these changes are not detectable with the present mAbs.
Apart from differences in the state of maturational arrest, the low and high grade designation essentially characterises the natural history of NHL, ie indolent in the former case and rapidly progressive in the latter. Thus, our results suggest the possibility that CAM expression could be related to differences in spontaneous aggressiveness. These results are in agreement with various reports showing that high levels of CD54 were associated with aggressive tumours, such as high grade NHL, 31, 37 progressive melanomas 38 and advanced stage transitional cell bladder cancer. 39 Strong expression of CD11a has been demonstrated in both highly aggressive and indolent tumours, such as active myeloma 40 and low grade NHL, 8, 41 respectively. In most instances, the cellular basis for tumour aggressiveness is unknown. In the case of Burkitt's NHL, that are rapidly progressive tumours, a defect in adhesion molecules partly explains escape from control by the immune system. 42 Indeed, CD54, CD11a and CD58 are known to facilitate contact between target cells and cytotoxic effectors. 23, [42] [43] [44] However, these CAMs were highly expressed in the other high grade NHL of our series. In this context, their role may be to offer a growth advantage by preferential interaction between the malignant B cells themselves (via their simultaneous expression of the CD54/LFA-1 ligand pair), as well as with environmental cells. T lymphocytes are particularly important in the environment of B lymphocytes. Since these tumours rapidly expanded, it could be supposed that the reactive T lymphocytes present could be either helper for malignant cell proliferation 10 or suppressive for the anti-tumour immune response. Stromal cells are also essential in the environment of B lymphocytes and CD54, LFA-1, as well as CD29/CD49d, have also been implicated in adhesion to fibroblasts 45 or follicular dendritic cells. 2, 16, 18 The strong correlation (P Ͻ 0.0001) between CD54 expression on malignant cells and Ki67, a marker of cell proliferation and tumour aggressiveness, also supports the idea that tumour behaviour could involve privileged contacts with neighbouring cells. Preferential interaction with the microenvironment has also been described in myeloma, in which LFA-1 expression has been correlated with active disease and with high labelling index. 40 In this pathology, tumour proliferation is largely dependent on interleukin-6 (IL-6) secreted by bone marrow stromal cells thanks to privileged contacts between them and plasma cells. 46 In situ, IL-6 secretion by reactive cells has also been shown in DLCL-IB, but IL-6-dependent proliferation of these lymphoma cells has not been studied. 47 Our finding, that DLCL-IB express the highest levels of adhesion molecules, raises the possibility that tumour activation could involve parallel mechanisms in both pathologies.
It has also been reported that cell-cell adhesion structures may influence the growth pattern of lymphoid malignancies. Indeed, concomitant expression of CD11a and CD54 has been shown to be a characteristic of B cell zone-derived NHL or germinal centre-derived NHL, particularly those with a nodular structure; conversely, lack of one or both antigens was more frequent in NHL with a diffuse pattern of tumour infiltration. 8, 16, 33 Accordingly, FL (nodular) and SLL (diffuse) from our series differed in their expression of CD54 (P = 0.0001). These results suggest that in low grade NHL, malignant cells remain localised because they are able to adhere to neighbouring cells. However, Table 2 shows that the same argument cannot be used in high grade NHL, where the expression of CD54 is ever higher than in FL. This highlights the possibility that the function of CAMs varies with the maturational state of the type of NHL.
In conclusion, there is marked heterogeneity in CAM expression within B-NHL and this partly correlates with the degree of differentiation of the malignant lymphocytes. The main conclusion was the observation that B-lymphocytes in high grade NHL express higher levels of CAMs than low grade subtypes. However, the exact significance of these findinds will requires functional studies to determine the role of theses CAMs in each subtype of NHL.
